Pain in knee osteoarthritis is associated with variation in the neurokinin 1/substance P receptor (TACR1) gene

Substance P (SP) is a pain‐ and inflammation‐related neuropeptide which preferentially binds to the neurokinin receptor 1 (NK1). SP and NK1 receptors have been implicated in joint pain, inflammation and damage in animal models and human studies of osteoarthritis (OA). The aim of this study was to test if genetic variation at the neurokinin 1 receptor gene (TACR1) is associated with pain in individuals with radiographic knee OA.

[1]  F. Blyth,et al.  Three subgroups of pain profiles identified in 227 women with arthritis: a latent class analysis , 2017, Clinical Rheumatology.

[2]  A. Valdes,et al.  Functional Morphology and Kinesiology the Genetics of Osteoarthritis: a Review , 2022 .

[3]  M. Hallberg.  Neuropeptides: Metabolism to Bioactive Fragments and the Pharmacology of Their Receptors , 2015, Medicinal research reviews.

[4]  Antonio González,et al.  Genetics of osteoarthritis. , 2015, Reumatologia clinica.

[5]  S. Hunt,et al.  Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome , 2014, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

[6]  A. Guermazi,et al.  Structural correlates of pain in joints with osteoarthritis. , 2013, Osteoarthritis and cartilage.

[7]  M. Fava,et al.  Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies , 2013, Journal of psychopharmacology.

[8]  H. Storm,et al.  Nociceptive stimuli responses at different levels of general anaesthesia and genetic variability , 2013, Acta anaesthesiologica Scandinavica.

[9]  S. Galea,et al.  A genome-wide association study of posttraumatic stress disorder identifies the retinoid-related orphan receptor alpha (RORA) gene as a significant risk locus , 2012, Molecular Psychiatry.

[10]  E. Claus,et al.  TACR1 genotypes predict fMRI response to alcohol cues and level of alcohol dependence. , 2013, Alcoholism, clinical and experimental research.

[11]  F. Cicuttini,et al.  Radiographic osteoarthritis and pain are independent predictors of knee cartilage loss: a prospective study , 2012, Internal medicine journal.

[12]  T. Spector,et al.  The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis , 2011, Annals of the rheumatic diseases.

[13]  P. Fayers,et al.  Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients , 2011, PAIN.

[14]  Stuart Maudsley,et al.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders. , 2010, CNS & neurological disorders drug targets.

[15]  P. Muglia,et al.  Genome-wide association study of major recurrent depression in the U.K. population. , 2010, The American journal of psychiatry.

[16]  S. Hunt,et al.  Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: A model of attention deficit hyperactivity disorder , 2009, Neuropharmacology.

[17]  P. Buckley.  Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism , 2009 .

[18]  Gun-Hee Kim,et al.  Basic fibroblast growth factor accelerates matrix degradation via a neuro‐endocrine pathway in human adult articular chondrocytes , 2008, Journal of cellular physiology.

[19]  J. McDougall,et al.  Age alters the ability of substance P to sensitize joint nociceptors in Guinea pigs , 2007, Journal of Molecular Neuroscience.

[20]  Tim D Spector,et al.  The UK Adult Twin Registry (TwinsUK) , 2006, Twin Research and Human Genetics.

[21]  R. Invernizzi,et al.  Blockade of tachykinin NK1 receptors attenuates stress‐induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex , 2006, Journal of neuroscience research.

[22]  S. Brain,et al.  Neuropeptides and their receptors: innovative science providing novel therapeutic targets , 2006, British journal of pharmacology.

[23]  P. Nieto,et al.  Tachykinins and tachykinin receptors: structure and activity relationships. , 2004, Current medicinal chemistry.

[24]  C. Cooper,et al.  Birth weight, weight at 1 y of age, and body composition in older men: findings from the Hertfordshire Cohort Study. , 2004, The American journal of clinical nutrition.

[25]  P. Devillier,et al.  mRNA expression of tachykinins and tachykinin receptors in different human tissues. , 2004, European journal of pharmacology.

[26]  F. Wilder,et al.  History of acute knee injury and osteoarthritis of the knee: a prospective epidemiological assessment. The Clearwater Osteoarthritis Study. , 2002, Osteoarthritis and cartilage.

[27]  W. Cruce,et al.  Effect of aging on the substance P receptor, NK-1, in the spinal cord of rats with peripheral nerve injury. , 2001, Somatosensory & motor research.

[28]  A. Janecka,et al.  Substance P: transmitter of nociception (Minireview). , 2000, Endocrine regulations.

[29]  S. Iyengar,et al.  Study of the analgesic effect of lanepitant in patients with osteoarthritis pain , 2000, Clinical pharmacology and therapeutics.

[30]  W. Kohrt,et al.  Effect of aging. , 2000, Nutrition reviews.

[31]  C. Lindh,et al.  Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc. , 1997, Scandinavian journal of rheumatology.

[32]  N. Rupniak,et al.  Non-specific inhibition of dopamine receptor agonist-induced behaviour by the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs. , 1994, European journal of pharmacology.

[33]  T. Spector,et al.  Cigarette smoking and risk of osteoarthritis in women in the general population: the Chingford study. , 1993, Annals of the rheumatic diseases.

[34]  K. Marshall,et al.  Substance P and arthritis: analysis of plasma and synovial fluid levels. , 1990, Arthritis and rheumatism.